Verona Pharma Announces December 2024 Investor Conference Participation
Verona Pharma Announces December 2024 Investor Conference Participation
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, .LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the following conferences in December 2024:
伦敦和北卡罗来纳洲，2024年11月19日，（环球新闻）--维罗纳制药公司（纳斯达克：VRNA）（"维罗纳制药"或"公司"）宣布，高级管理人员将于2024年12月在以下会议上进行公司概况演示：
Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Time: 12:00 p.m. ET / 5:00 p.m. GMT
Location: New York, NY
派杰投资第36届医疗保健年会
日期：2024年12月3日星期二
时间：下午12:00 /格林威治时间下午5:00
地点：纽约，纽约州
7th Annual Evercore HealthCONx Conference
Date: Wednesday, December 4, 2024
Time: 3:00 p.m. ET / 8:00 p.m. GMT
Location: Miami, FL
第七届evercore HealthCONx大会
日期：2024年12月4日星期三
时间：下午3:00 Et / 下午8:00 GMT
地点：佛罗里达州迈阿密
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, .
每场会议演示的网络广播将在公司网站投资者页面的活动和演示链接上提供。
For further information please contact:
要了解更多信息，请联系：
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications |
IR@veronapharma.com |
|
Argot Partners (US Investor Enquiries) |
Tel: +1-212-600-1902 verona@argotpartners.com |
|
Ten Bridge Communications International / US Media Enquiries |
Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com |
| Wendy Ryan |
| 维罗纳制药股份有限公司 | 电话：+1-844-341-9901 |
| 维多利亚·斯图尔特，投资者关系和通信高级董事 关系与通信 |
IR@veronapharma.com |
| 阿哥特合伙人。 （美国投资者咨询） |
电话：+1-212-600-1902 verona@argotpartners.com |
| Ten Bridge Communications 国际/美国媒体询问 |
电话：+1-781-316-4424 tbcverona@tenbridgecommunications.com |
| Wendy Ryan |
About Verona Pharma
关于维罗纳制药
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit .
维罗纳制药是一家专注于开发和商业化创新治疗慢性呼吸道疾病的生物制药公司，这些疾病存在重大的医疗需求。Ohtuvayre（ensifentrine）是该公司的第一个商业产品，也是用于COPD维持治疗的第一个吸入疗法，结合了支气管扩张剂和非甾体类抗炎活性于一身。Ensifentrine在非囊性纤维化支气管扩张症、囊性纤维化、哮喘和其他呼吸系统疾病中具有潜在应用。欲了解更多信息，请访问 .
